Non-Profit Trusted Source of Non-Commercial Health Information
The Original Voice of the American Academy of Anti-Aging, Preventative, and Regenerative Medicine
logo logo
Genetic Research

News From Elixir Pharmaceuticals

14 years, 6 months ago

1562  0
Posted on Nov 17, 2004, 3 a.m. By Bill Freeman

A press release notes a new license and research direction. "Elixir Pharmaceuticals, Inc. announced today that it has licensed intellectual property [relating to] NaCT-1, a human ortholog of the longevity gene, INDY . Our research suggests that aging is a carefully regulated metabolic process. The INDY gene product is an excellent example of an anti-aging target that has been proven to play a role in the cellular regulation of lipid and carbohydrate metabolism.
A press release notes a new license and research direction. "Elixir Pharmaceuticals, Inc. announced today that it has licensed intellectual property [relating to] NaCT-1, a human ortholog of the longevity gene, INDY ... Our research suggests that aging is a carefully regulated metabolic process. The INDY gene product is an excellent example of an anti-aging target that has been proven to play a role in the cellular regulation of lipid and carbohydrate metabolism. ... a drug that inhibits NaCT-1 may provide a pharmacological means to reduce fat and cholesterol synthesis and thus enable control of [excess lipids, cholesterol and body fat] ... Elixir has an interest in the NaCT-1 transporter as a drug target for the development of pharmaceuticals to improve human health and prolong youthfulness."

View the Article Under Discussion: http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20041116005245&newsLang=en
Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/
http://www.longevitymeme.org/news/view_news_item.cfm?news_id=1319

Subscribe to our Newsletter

WorldHealth Videos

WorldHealth Sponsors